 |
|
Antithrombin III Level, Fibrinogen Level, and Platelet Count Changes With Adjuvant Tamoxifen Therapy
Richard R. Love, MD, MS;
Tanya S. Surawicz;
Eliot C. Williams, MD
Arch Intern Med. 1992;152(2):317-320.
Abstract
| |
Adjuvant therapy for breast cancer with tamoxifen is suggested to be of benefit to both women with negative and women with positive axillary nodes, and treatment lasting several years is currently being investigated. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible mechanisms of this effect, we evaluated changes in antithrombin III levels, fibrinogen levels, and platelet counts in 140 postmenopausal women with surgically resected breast cancer who were disease free and participating in a double-blind, placebo-controlled, randomized toxicity study of tamoxifen. Antithrombin III levels, elevated at baseline evaluation, decreased in tamoxifentreated subjects at 6 months, but no subject exhibited a drop to clinically significant levels. Fibrinogen levels decreased 15% (0.4 g/L) in tamoxifen-treated subjects at 6 months. Platelet counts decreased 7% to 9% from baseline to evaluations at 3, 6,12,18, and 24 months in tamoxifen-treated subjects. While these changes do not explain the possible small thrombophlebitis-promoting effect of tamoxifen, the decrease in fibrinogen levels might be expected to be associated with a decreased risk of arterial thrombosis.
(Arch Intern Med. 1992;152:317-320)
Author Affiliations
From the Cancer Prevention Program, University of Wisconsin Clinical Cancer Center, and the Departments of Human Oncology and Medicine, University of Wisconsin, Madison.
Footnotes
Accepted for publication September 20, 1991.
Reprint requests to the Cancer Prevention Center, 1300 University Ave, Suite 7C, Madison, WI 53706 (Dr Love).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021
Robins et al.
Neuro Oncol Duke 2006;8:47-52.
ABSTRACT
| FULL TEXT
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
Fabian and Kimler
JCO 2005;23:1644-1655.
FULL TEXT
The Effects of Tamoxifen and Its Metabolites on Platelet Function and Release of Reactive Oxygen Intermediates
Vitseva et al.
J. Pharmacol. Exp. Ther. 2005;312:1144-1150.
ABSTRACT
| FULL TEXT
Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
Erman et al.
Ann Oncol 2004;15:1622-1626.
ABSTRACT
| FULL TEXT
Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer
Saif et al.
Ann Oncol 2004;15:1366-1372.
ABSTRACT
| FULL TEXT
Tamoxifen and Cardiac Risk Factors in Healthy Women : Suggestion of an Anti-inflammatory Effect
Cushman et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:255-261.
ABSTRACT
| FULL TEXT
Selective Estrogen Receptor Modulators: Clinical Spectrum
Cosman and Lindsay
Endocr. Rev. 1999;20:418-434.
ABSTRACT
| FULL TEXT
State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy
von Tempelhoff et al.
CLIN APPL THROMB HEMOST 1999;5:92-104.
Effect of Tamoxifen on Measurements of Hemostasis in Healthy Women
Mannucci et al.
Arch Intern Med 1996;156:1806-1810.
ABSTRACT
|
